Novo's Bid to Block Lilly's GLP-1 Ads: Preliminary Injunction Motion Filed, No Ruling Yet
The false-advertising war between Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) escalated from complaint to motion. After filing suit in the District of New Jersey on July 21, 2026, Novo moved for a preliminary injunction seeking to immediately halt Lilly's comparative DTC ads for Zepbound and Mounjaro while the case proceeds:
"Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly.12" — CNBC, July 24, 2026
The motion, filed under the Lanham Act, argues Lilly's ads "rely on outdated clinical trial data." Key filings quotes via MobiHealthNews:
"Novo Nordisk seeks only to prevent Lilly from continuing to mislead consumers with deceptive, outdated comparisons. Novo Nordisk tried to resolve this dispute without Court intervention — it sent Lilly a detailed cease-and-desist letter in April 2026 and, after filing this lawsuit, again demanded that Lilly pull the false ads." — MobiHealthNews
"Lilly refused, calling its advertising 'truthful' and 'transparent,' rejecting Novo Nordisk's demands in their entirety, and making clear it has no intention of modifying the challenged campaigns."
Novo's core theory: "Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly's medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true." Notably, Novo is not seeking to block Lilly from selling or advertising its drugs — only the comparative claims. The injunction would apply only to ads making the disputed comparisons (Fierce Pharma).
Status as of September 21, 2026: no ruling on the preliminary injunction has surfaced; the registered one-shot watch (fire date Dec 31, 2026) stays open. Legal commentary frames the stakes as precedent-setting: the case "asks a New Jersey federal judge to decide when scientifically accurate clinical-trial results" become misleading as the label evolves (Law.com).
What it means: The courtroom fight mirrors the commercial one — Novo is litigating the same head-to-head efficacy gap that is driving its share losses (Oral GLP-1 Battle Flips: Foundayo Surges 21% to 64K Weekly Scripts While Wegovy Pill Stalls at ~182K). An injunction forcing Lilly to pull or soften comparative ads would remove one of the loudest megaphones amplifying tirzepatide's superiority messaging during the critical oral-launch window.
-
An instance of In a saturated drug market, head-to-head superiority is manufactured by comparator selection. — With the molecules clinically close, the duopoly litigates each other's comparative superiority claims as false advertising rather than competing on data. ↩︎
-
An instance of Blockbuster metabolic exclusivity is decided in the courtroom rather than the clinic. — Rather than contest the efficacy gap in trials, Novo is litigating to silence the comparative advertising amplifying it — blockbuster exclusivity contested in court, not the clinic. ↩︎